Survival time distribution of advanced stage metastatic melanoma among whites and minority populations in Florida, 1996-2010.
Differences in genetic profiles and environmental exposure may impact on the prognostic factors of metastatic melanoma with major implications on the survival of minorities with advanced stage disease at presentation. This study determines the impact of the stage at diagnosis, tumor location, grade, and histologic type on overall survival time distribution among non–Hispanic Whites (NHW), HW and African– Americans (AA) in Florida. A dataset of 80,349 NHW, AA and HW Stage III and IV metastatic melanoma patients at presentation was obtained from the Florida Cancer Data System. Measures related to the impact of the stage at diagnosis, anatomic/primary site or tumor location, grade, and histologic type on overall survival time distribution across racial groups are reported. Data were analyzed using SAS. Mean time univariate and multivariate survival statistics across races were analyzed using Kaplan–Meir method and the nonparametric log-rank tests were used to test the homogeneity of survival curves. Significant differences in survival time are reported among the races in primary sites, histology, and stage at diagnosis, but not in terms of tumor grade; survival curve distributions were still significantly different even when adjustments were made for age, nodes, lymphatic invasion, and tumor size.
Hu S, Parmet Y, Allen G, Parker D F, Ma F, Rouhani P, and Kirsner R S (2009) Disparity in Melanoma. Arch. Dermatol. 145:12, 1369-1374.
Balch CM, Gershenwald JE, Song S et al. (2009). Final version of 2009 AJCC Melanoma Staging and Classification. J Clin Oncol 27(36):6199-6206.
Lee JA (2010). The determination of melanoma state at diagnosis. Dermatol Res Prat 1-3.
Xu X, Chen L, Guerry D, Dawson PR, Hwang W, VanBelle P, Elder DE, Zhang PJ, Ming ME, Schuchter L and Gimotty PA (2011). Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 18(1):229-237.
Balch CM, Gershenwald JE, SooNg S et al. (2010). Multivariate analysis of prognostic factors among 2,313 patient with Stage III melanoma: Comparison of nodal micro-metastasis versus macro-metastasis. J Clin Oncol 28(14):2452-2459.
Hu S, Parker DF, Thomas AG, Kirsner RS (2004) Advanced presentation of melanoma in African Americans: the Miami-Dade County experience. J Am Acad Dermatol 51(6):1031-1032.
Hu S, Soza-Vento RM, Parker DF, Kirsner RS (2006) Comparison of stage at diagnosisof melanoma among Hispanic, black, and white patients in Miami-Dade County, Florida. Arch Dermatol 142(6):704-708.
Rouhani P, Hu S and Kirsner R S (2008) Melanoma in Hispanic and Black Americans. Cancer Conrol, 15:3, 248-253.
Bellows CF, Belafsky C, Fortgang IS and Beech DJ (2001) Melanoma in African Americans: Trends in Biological and Clinical Characteristics over Two Decades. J Surg Oncol 78:10-16.
Bradford PT (2009) Skin cancer in skin of color. Dermatology Nursing 21(4):170-177.
Crest R D and Holly E A (1997) Incidence of cutaneous melanoma among non-Hispanic Whites, Hispaniocs, Asians and Blacks: an analysis of the California Cancer Registry data, 1988-1993. Cancer Causes and Control, 8; 246-252.
Rouhani P, Pinheiro P S, Sherman R, Arheart K, Fleming L E, MacKinnon J and Kirsner R S (2010). Increasing Rates of Melanoma Among Nonwhites in Florida Compared With the United States. Arch. Dermatol. 146:7, 741-746.
Byrd KM, Wilson DC, Hoyler SS et al. (2004). Advanced presentation of melanoma in African Americans. J Am Acad Dermatol 50:21-24.
Merrill RM, Pace ND and Elison AN (2010). Cutaneous malignant melanoma among White Hispanics and Non-Hispanics. Ethnicity & Disease 20:353-358.
Krementz ET, Sutherland CM, Carter RD et al. (1976). Malignant melanoma in the American Black. Ann Surg 5:533-541.
Hudson DA, Krige JE and Stubbings H (1998). Planter melanoma: results of treatment in three population groups. Surgery 124(5):877-882.
Hudson DA and Krige JE (1995). Melanoma in Black South Africans. J Am Coll Surg 180(1):65-71.
International Classification of Diseases for Oncology ICD-0-3. http://codes.iarc.fr/usingicdo.php (Accessed October, 2018).
SEER Training: Melanoma Staging Schemes
https://training.seer.cancer.gov/staging/systems/schemes/melanoma.html. (Accessed October, 2018)
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site 2013.
Wu X, Eide MJ, King J, Daraiya M, Huang Y, Wiggins C, Barnholtz-Sloan JS, Martin N, Cokkinides V, Miller J, Patel P, Ekweme DU, and Kim J (2011). Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States. J Am Acad Dermatol 65(5): S26.e1-e13.
Sandru A, Voinea S, Panaitescu E and Blidaru A (2014). Survival rates of patients with metastatic malignant melanoma. J Med and Life, 7(4):572-576. 22.
Pollack LA, Li J, Berkowitz Z, Weir HK, Wu X, Ajani UA, Ekweme DU, Li C and Pollack BP (2011). Melanoma survival in the United States, 1992-2005. J Am Acad Dermatol 65(5 Suppl 1): S78-86.
Homsi J, Kashani-Sabet M, Messina JL and Daud A (2005). Cutaneous melanoma: prognostic factors. Cancer Control 12(4) 223-229.
Masback A, Olsson H, Westerdahl J, Ingvar C and Jonsson N (2001) Prognostic factors in invasive malignant melanoma: A population-based study and review. Melanoma Research 11(5): 435-445.
Mervic L (2012). Time course and pattern of metastasis differ between men and women. PloS One 7(3): 572-576.
Blidaru VS, Panaitescu E and Sandru A (2016). Impact of gender and primary tumor location on outcome of patients with cutaneous melanoma.
Ozgen A (2014). A single institution retrospective analysis of malignant melanoma. J Cancer Res Therapeut.10 (1): 38-42.
Bradford PT, Goldstein AM, McMaster ML and Tucker MA (2009). Acral Lentiginous Melanoma: Incidence and Survival patterns in the United States, 1986-2005. Arch Dermatol 145(4): 427-434.
Ward-Peterson M, Acun˜a JM, Alkhalifah MK, Nasiri AM, Al-Akeel ES, Alkhaldi TM, Dawari SA and Aldaham SA (2016). Association Between Race/Ethnicity and Survival of Melanoma Patients in the United States Over 3 Decades: A Secondary Analysis of SEER Data. Medicine 95(17): 1-6.
Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE< Ross MI and Du XL (2006). Ethnic differences among patients with cutaneous melanoma. Arch Intern Med, 166(17): 1907-1914.
Forman SB, Feringer TC, Dalton SJ, Sasaki SR, Lobow LF and Elston DM (2008). Is superficial spreading melanoma still the most common form of malignant melanoma? J Am Acad Dermatol, 58(6): 1013-1020.
Schuchter L, Schultz DJ, Synnestvedt M, et al. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med. 1996;125: 369-375.
Chang CK, Jacobs IA, Vizgirda VM and Salti GI (2003). Melanoma in the elderly patient. Arch Surg, 138(10): 1135-1138.
Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
Harlan LC, Lynch CF, Ballard-Barbash R and Zeruto C (2011). Trends in treatment and survival for local and regional cutaneous melanoma in a US population-based study. Melanoma Res 21(6): 547-554.
Giorgadze TA, Zhang PJ, Pasha T, Coogan PS, Acs G, Elder DE and Xu X (2004). Lymphatic vessel density is significantly increased in melanoma. J Cutan Pathol 31(10): 672–677.
Barth A, Wanek LA and Morton DL (1995). Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181(3):193-201.
Xu X, Gimotty PA, Guerry D, Karakousis G, and Elder DE (2014). Lymphatic Invasion as a Prognostic Biomarker in Primary Cutaneous Melanoma. Methods Mol Biol 1102: 275-286.